Identification of CFTR activators and inhibitors: chance or design?

Current Opinion in Pharmacology
Luis J V Galietta, Oscar Moran

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-activated Cl(-) channel expressed in various epithelial cells, and is a pharmacological target for activators and inhibitors. Activators are useful for the pharmacotherapy of cystic fibrosis, specifically for those mutations that affect CFTR protein by reducing its ability to stay in the open state. Conversely, inhibitors are potentially useful to treat secretory diarrhoea caused by enterotoxins, as the CFTR is the main route for Cl(-) flux in the intestine. Recently, a variety of potent modulators of the CFTR Cl(-) channel activity have been identified by high-throughput screening of a large collections of small molecules. The identification of CFTR activators and inhibitors with novel chemical scaffolds might help with the rational design of compounds with improved pharmacological properties.

Citations

Oct 27, 2010·Journal of Computer-aided Molecular Design·Ori KalidHanoch Senderowitz
Jun 6, 2009·The Journal of Pharmacology and Experimental Therapeutics·Antonella CaputoLuis J V Galietta
Sep 26, 2006·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Peter C Austin
Aug 18, 2009·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Peter C Austin
Apr 28, 2006·American Journal of Physiology. Cell Physiology·Susan Troutman HalmDan R Halm
Dec 15, 2017·Developmental Neurobiology·Nicole A SuarezAlysson R Muotri
Jul 26, 2015·American Journal of Physiology. Lung Cellular and Molecular Physiology·Guiying Cui, Nael A McCarty

❮ Previous
Next ❯

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.